Are you looking for expert advice...

Healthcare professionals in Scotland are invited to attend a free clinical half-day event in Aberdeen focused on the future of clinically led medical cannabis care.

The Clinician Summit: Prescribing Cannabis-Based Products for Medicinal Use will take place on 10 June 2026, from 2pm to 6pm, at ONE, Opportunity North-East, Aberdeen. The event is hosted by Waterside and will bring together experienced prescribers, clinicians and healthcare professionals for an afternoon of education, discussion and networking.

The session will explore the current UK medical cannabis landscape, practical prescriber perspectives, patient stories, clinical team opportunities and the development of Waterside’s planned clinic model in Scotland.

Hear from leading medical cannabis prescribers

The event offers a valuable opportunity to hear directly from members of the Society’s Executive Committee, including some of the UK’s most experienced clinicians working in cannabis-based medicines.

A clinical discussion for Scottish healthcare professionals

This event is designed for healthcare professionals who want to understand more about medical cannabis prescribing, shared care, clinical governance and patient pathways.

It is particularly relevant for GMC Specialist Register clinicians, GPs with an interest in shared care, nurses and nurse prescribers, pharmacist prescribers, and healthcare professionals interested in medical cannabis care.

The afternoon will also include a Q&A and networking session, giving attendees the chance to meet experienced prescribers, ask practical questions and learn more about clinical team opportunities.

Register for the event

Places are limited and the event is free to attend. Clinicians and healthcare professionals interested in medical cannabis care are encouraged to register early.

Register via eventbrite

This is a strong opportunity to hear from leading UK prescribers, gain insight into the realities of medical cannabis practice, and take part in an important clinical conversation about the future of cannabis-based medicines in Scotland.

Medical cannabis should be discussed in mental health with the same seriousness as any other developing area of medicine: neither romanticised nor dismissed. Recent debate has rightly drawn attention to the need for better evidence, clearer standards and stronger clinical governance. But the conclusion should not be that cannabis-based medicinal products have no place in mental health care.

The more accurate conclusion is that the evidence is uneven across indications, that the literature is still developing, and that prescribing must be careful, specialist-led and evidence-informed. That position is entirely consistent with the Medical Cannabis Clinicians Society’s updated Good Practice Guide, which states that CBMPs can be prescribed safely where there is appropriate assessment, oversight and follow-up, and that prescribing should remain structured, accountable and aligned with wider professional standards.1

Medical cannabis is not a speculative field

Outside psychiatry, the therapeutic role of medical cannabis is already established and widening. NICE guidance already addresses cannabis-based medicines in severe treatment-resistant epilepsy, spasticity in multiple sclerosis, chronic pain and chemotherapy-induced nausea and vomiting.2

The evidence base is still developing, but it already includes signals that are clinically relevant. In ADHD, the EMA-C pilot RCT of Sativex in 30 adults reported nominal improvements in hyperactivity/impulsivity and inhibition. More recently, a phase 3 randomised placebo-controlled trial of a full-spectrum cannabis extract in chronic low back pain met its primary endpoint and showed statistically significant improvements in pain, sleep and physical function versus placebo.3 

There is also a clear mechanistic rationale for considering cannabinoids in psychiatric practice. The endocannabinoid system is not simply involved in pain or appetite; it is a neuromodulatory system with recognised roles in emotional processing, stress response, fear regulation, synaptic plasticity and neuroplasticity. A 2025 review13 specifically examined the contribution of the endocannabinoid system to the neurobiology of emotions, describing its relevance to brain circuits involved in mood, anxiety, stress and adaptive emotional regulation. 

Mental health should therefore not be discussed as though cannabis were a wholly speculative therapy; it sits within a broader clinical field in which evidence is already stronger for some conditions than for others.

The MCCS Good Practice Guide reflects this reality. It identifies anxiety and related disorders, sleep disorders and symptom clusters such as pain, sleep disturbance and anxiety among the common indications encountered in practice, while explicitly acknowledging that the evidence base varies between conditions.1 Some areas rely more heavily on established evidence; others depend more on emerging evidence, real-world data and clinical experience. That is not a weakness unique to cannabis medicine. It is a familiar feature of many areas of specialist prescribing, particularly where patients present with complex, overlapping symptoms and have already failed, not tolerated, or derived insufficient benefit from conventional options.

Evidence gaps are not the same as evidence of no effect

The recent 2026 Lancet Psychiatry review is an important contribution and should be taken seriously. It examined 54 randomised trials involving 2,477 participants and concluded that there was little RCT evidence of efficacy for several mental and substance use disorders. It also found no randomised controlled trial evidence for depression,4 and a 202613 review found that controlled evidence for cannabinoids in OCD remains very limited. That matters. But it does not follow that cannabinoids have been shown to be ineffective in depression or OCD, or that all psychiatric use is unjustified. In depression in particular, the review highlights an evidence gap, not evidence of no effect. In other words, absence of RCT evidence is not the same as proof of therapeutic futility.

This distinction matters because clinicians do not treat meta-analyses in the abstract; they treat patients in front of them. In real-world practice, many patients seeking CBMPs for mental health symptoms have chronic anxiety, trauma-related symptoms, poor sleep, autonomic hyperarousal, pain, and marked impairment in quality of life. They have often already tried multiple licensed treatments, psychological interventions, or both. The MCCS framework is clear that CBMPs are not first-line treatments and that conventional evidence-based options should normally have been appropriately explored first. But it is equally clear that prescribing is ultimately based on individual clinical judgment, patient need, risk profile and informed consent.1

Those real-world data are now too substantial to ignore. Project Twenty21 has reported consistent improvements in symptoms, general health and quality of life in large cohorts of UK patients, and its sleep analysis found clinically significant improvements sustained for up to 12 months together with reduced use of sleep medication.5,8 The UK Medical Cannabis Registry has shown similar signals in generalised anxiety disorder and PTSD, with improvements in anxiety, sleep and health-related quality of life and with most reported adverse events mild or moderate.6,9 Most strikingly for current debate, registry data in depression now extend to 24 months and show sustained improvement in depression scores, anxiety, sleep and quality of life in selected patients.10 These studies do not prove causation. They do, however, show that the lived clinical experience of benefit is not fanciful and should not be dismissed as irrelevant simply because it comes from observational data.5,6,8-10 

International registry data point in the same direction. A large Australian longitudinal cohort of 3,961 cannabis-naive patients prescribed oral medicinal cannabis reported sustained improvements across multiple validated outcomes over two years and concluded that treatment was safe and well tolerated, while explicitly acknowledging the limits of real-world data for causal inference. This is the correct balance: neither overstatement nor dismissal. Real-world evidence cannot settle every question, but it is highly informative on tolerability, safety, prescribing patterns and patient-reported outcomes in routine care.7

Risk must be managed, not denied

A supportive clinical position does not mean an uncritical one. The MCCS guidance is explicit that psychiatric prescribing requires particular care. It recommends structured psychiatric risk assessment, review of medical records, consideration of risk, and closer monitoring in higher-risk cases. It also emphasises that THC-containing CBMPs require additional caution in patients with a history of psychosis or schizophrenia, while noting that CBD-dominant products may be considered in selected cases because of their non-intoxicating and potentially antipsychotic profile.1 The point is not to deny risk, but to manage it properly.

That is why the most credible position for a clinician-led society is neither overclaiming nor retreat. Medical cannabis has a legitimate place in mental health care for selected patients. The evidence is stronger for some conditions and symptom domains than for others. For depression, the central problem is not that cannabinoids have been disproven, but that high-quality randomised trials are still lacking while observational evidence continues to grow.4 The appropriate response is therefore clear: prescribe carefully, select patients properly, document honestly, monitor closely, and continue to build the evidence base. That is not special pleading for cannabis – it is simply what responsible evidence-based medicine looks like in a developing field.

Supporting clinicians to prescribe safely in psychiatric practice

For clinicians who want to build confidence in this area, the Society is also developing a dedicated Psychiatry Evidence Base, bringing together the current research, clinical evidence and real-world data relevant to mental health prescribing. This will sit alongside the Society’s wider evidence base series and support clinicians in making careful, informed decisions in this complex area of practice.

The Society has also launched a new online training course for healthcare professionals: Medical Cannabis and Mental Health: Evidence, Clinical Judgment and Responsible Prescribing.

Written by Dr Luisa Searle, Consultant Psychiatrist, the course provides a practical, clinically focused introduction to the use of cannabis-based medicinal products in psychiatric practice. It explores how CBPMs may be considered in patients with anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder and depression, while making clear that these treatments are not first-line options and require careful patient selection, risk assessment, monitoring and documentation.

The course covers the role of CBD and THC, the relationship between the endocannabinoid system and psychiatric symptoms, contraindications and cautions, including psychosis vulnerability, mood destabilisation, substance use disorder, suicidality, drug interactions and the risks associated with higher THC exposure. Through condition-specific teaching and practical case studies, learners will gain a clearer understanding of how CBPMs may be used as adjunctive treatment within a broader care plan, while maintaining good governance, shared care communication and professional accountability.

Take the course

Please note, CPD accreditation is pending. Learners will receive a certificate on completion, with an updated certificate issued once CPD accreditation is confirmed.

References

  1. Medical Cannabis Clinicians Society. Good Practice Guide for Prescribers of CBMPs. Version 4. London: MCCS; 2026 Apr
  2. National Institute for Health and Care Excellence. Cannabis-based medicinal products. NICE guideline NG144. London: NICE; 2019 [updated 2021].
  3. Karst M, Meissner W, Sator S, Keßler J, Schoder V, Häuser W, et al. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial. Nat Med. 2025;31:4189-4196.
  4. Wilson J, Dobson O, Langcake A, Mishra P, Bryant Z, Leung J, et al. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2026;13(4):304-315.
  5. Schlag AK, O’Sullivan SE, Zafar RR, Nutt DJ. Characteristics of patients and patterns of cannabis-based medicinal product use in Project Twenty21: an observational study of 2833 patients in the UK. J Psychopharmacol. 2023;37(7):730-739.
  6. Warner-Levy J, Erridge S, Clarke E, McLachlan K, Coomber R, Asghar M, et al. UK Medical Cannabis Registry: a cohort study of patients prescribed cannabis-based oils and dried flower for generalised anxiety disorder. Expert Rev Neurother. 2024;24(12):1193-1202.
  7. Vickery AW, Roth S, Ernenwein T, Kennedy J, Washer P. A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years. PLoS One. 2022;17(11):e0272241.
  8. Lynskey MT, Athanasiou-Fragkouli A, Thurgur H, Schlag AK, Nutt DJ. Changes in sleep quality among patients prescribed medicinal cannabis: real-world evidence from Project Twenty21. Drug Sci Policy Law. 2025;11:20503245251362491.
  9. Datta A, Erridge S, Warner-Levy J, Clarke E, McLachlan K, Coomber R, et al. UK medical cannabis registry: an updated clinical outcomes analysis of patients with post-traumatic stress disorder. Expert Rev Neurother. 2025;25(5):599-607.
  10. Lillywhite E, et al. UK Medical Cannabis Registry: a two-year case series of clinical outcomes in depression. J Affect Disord. 2026;399:121130.
  11. Pontes LR, Ribeiro S. Contributions of the endocannabinoid system to the neurobiology of emotions: Advances and perspectives. Progress in Brain Research. 2025;296:65-93. doi:10.1016/bs.pbr.2025.08.001. 
  12. Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. European Neuropsychopharmacology. 2017;27(8):795-808. doi:10.1016/j.euroneuro.2017.05.005. 
  13. Van Ameringen M, Patel V, Patterson B, Hopkinson P, Rahat M. New treatments for OCD? Evidence for cannabinoids and psychedelics. Journal of Psychiatric Research. 2026;193:172-178. doi:10.1016/j.jpsychires.2025.11.021.

The Medical Cannabis Clinicians Society is pleased to be a media partner for Cannabis Europa London 2026, which returns to the Barbican Centre on 26 – 27 May.

Now in its thirteenth edition, Cannabis Europa brings together policymakers, clinicians, scientists, investors, entrepreneurs and sector leaders for two days of high-level discussion on the future of cannabis in Europe.

For MCCS, this is an important opportunity to support serious, informed conversation about the direction of the sector, particularly at a time when the UK medical cannabis landscape continues to face both progress and persistent challenges.

Since medical cannabis was rescheduled in the UK in November 2018, the number of private prescriptions has continued to grow, with more patients seeking treatment where conventional options have not provided adequate relief. However, NHS access remains extremely limited, and many clinicians, patients and policymakers continue to ask what needs to change if the UK is to develop a fair, safe and clinically robust medical cannabis framework.

That question sits at the heart of one of the sessions we are particularly looking forward to.

State of Play: United Kingdom

On the programme for Cannabis Europa London 2026 is State of Play: United Kingdom, a fireside discussion with Tonia Antoniazzi MP and Sarah Sinclair of Cannabis Health.

This session will explore the stubborn gap between policy and practice in the UK. Nearly eight years after medical cannabis was rescheduled, access through the NHS remains limited, while private clinics continue to grow in response to patient demand.

The discussion will ask whether the UK is finally ready to move from caution to action, and what would need to happen for the country to realise its potential within the current framework. For MCCS, these are vital questions. Clinicians working in this field need clear guidance, appropriate training, consistent standards and a policy environment that recognises both the therapeutic value of cannabis-based medicines and the practical barriers that still exist.

Key themes across the programme

We are also looking forward to the panel Can Cannabis Help to Close the Gender Health Gap? From Stigma to Solutions in Women’s Health.

Women’s health remains an area where patients often report delayed diagnosis, stigma and limited treatment options. The role of medical cannabis in this space is an important and timely discussion, particularly as more patients seek support for complex, chronic and under-recognised symptoms.

Another session of interest is Beyond Flower: Is Europe’s Medical Cannabis Market Turning Pharmaceutical?

For years, flower has played a central role in Europe’s medical cannabis market, valued by many patients for its familiarity and rapid onset. However, as new national frameworks emerge, regulators across Europe appear to be showing increasing preference for products that look, dose and behave more like conventional medicines.

This raises important questions for clinicians, regulators, industry and patients. Do standardised formats such as extracts, capsules, pastilles and medical devices help build trust and improve prescribing confidence? Or could a move away from flower reduce patient choice and limit access to products that some patients find effective?

These are exactly the kinds of discussions that need to happen openly and seriously as the sector develops.

Looking ahead

Cannabis Europa London 2026 offers a valuable space for informed discussion, practical insight and meaningful connection across the European cannabis sector.

MCCS is looking forward to hearing from the speakers, meeting colleagues from across the sector and supporting conversations that help move medical cannabis policy, education and clinical practice forward.

We look forward to seeing many of you at the Barbican in May.

MCCS stakeholders can access discounted tickets using the following codes:

MCCS10 for 10% off Standard tickets
MCCS15 for 15% off VIP tickets

You can purchase tickets here.

Each month, we bring together the key news stories shaping the medical cannabis landscape in the UK and beyond. From policy developments and emerging research to clinical practice, patient experience and sector growth, this update highlights the issues driving debate, influencing care, and affecting access for patients and clinicians alike.

It is designed to keep our members and stakeholders informed, grounded in evidence, and connected to what matters most across this rapidly evolving field.

Welsh Liberal Democrats pass motion to protect cannabis patients

The Welsh Liberal Democrats have passed a motion which aims to safeguard medical cannabis patients and protect them from discrimination. The party voted overwhelmingly to approve the motion, brought by Clwyd East and Flintshire Liberal Democrats, with Flintshire County Council becoming the first local authority to adopt the policy this month. It aims to safeguard patients prescribed cannabis-based medicines in the UK and address the stigma and discrimination many report experiencing related to their medication, including from police, housing associations, and employers.

🔗 Read more

Ireland to review of medical cannabis programme

The Irish government has appointed a public health academic to chair a formal review of its now five-year-old Medical Cannabis Access Programme (MCAP) following months of parliamentary pressure. Despite launching in 2021, a recent written ministerial answer reveals that less than 100 patients have been approved for medical cannabis treatment under the MCAP scheme.

Professor Shane Allwright, a retired Trinity College Dublin epidemiologist, will lead the Review of Access to Cannabis for Medical Use, set to examine the current operation of both the MCAP and the ministerial licence pathway, and assess whether the programme’s narrow eligibility criteria should be expanded.

🔗 Read more

CIC launches new guidance for travelling with medical cannabis

The Cannabis Industry Council has published a new patient-focused guide, Travelling with Medical Cannabis, offering practical advice for UK patients navigating the complex and often inconsistent rules around travelling with prescribed medical cannabis. Differences in legal frameworks, inconsistent enforcement, and limited awareness among authorities and transport providers have created significant challenges for patients relying on their medication. The CIC is calling for increased education among airlines, law enforcement, and border authorities to ensure patients are treated fairly and consistently. The guide is now available to download for free here.  

🔗 Read more

Join the Society

If you want to stay informed, supported, and part of the independent clinical voice shaping medical cannabis in the UK, join the Medical Cannabis Clinicians Society.

Membership gives you access to expert guidance, CPD-accredited education, peer support, and regular sector updates like this one. Join the Society to be part of the conversation and help drive better, evidence-based care.

The Medical Cannabis Clinicians Society (MCCS) has today launched its latest addition to the Evidence Base Series: a comprehensive review of the clinical evidence for cannabis-based medicinal products (CBMPs) in the treatment of pain.

Pain remains one of the most common reasons patients seek medical cannabis, and one of the most debated areas in terms of evidence, guidance, and clinical confidence. This publication brings together a fragmented evidence base into a clear, structured resource to support informed prescribing decisions.

What stands out in this work is the sheer scale of the evidence and how it has been brought together. The evidence base draws on 264 references, with 124 studies reviewed and summarised in detail. These include randomised controlled trials, observational studies, open-label studies, and case reports. Rather than presenting isolated findings, the publication brings these data together in a way that allows clinicians to see patterns, consistency, and areas of uncertainty across the wider body of research.

One of the persistent challenges in medical cannabis has been the perception that the evidence is either limited or unclear. In reality, the issue is often not absence of data, but fragmentation. Studies exist across different formats, populations, and methodologies, making it difficult to interpret the evidence in a way that is clinically useful. This publication addresses that problem by synthesising the data into a single, accessible resource.

➡️ Purchase your copy today

A clear, evidence-led approach to prescribing

Professor Mike Barnes, Chair of the Medical Cannabis Clinicians Society, highlights the importance of this approach:

“There is not an absence of evidence in this area, but there are different types of evidence, often spread across a wide and fragmented literature. Clinicians are not short of studies, but they are short of time. Bringing together this volume of evidence in a clear and structured way allows prescribers to make informed decisions based on the totality of the data, not just individual papers.”

The publication focuses on the role of cannabinoids, particularly THC and CBD, across a range of pain conditions, including chronic pain, neuropathic pain, and cancer-related pain. It examines not only efficacy, but also safety, tolerability, and the balance of risk and benefit in real-world clinical settings.

By grounding its analysis in both clinical trials and real-world evidence, the MCCS aims to provide a more complete picture. Observational data and case series are not positioned as replacements for controlled trials, but as complementary sources of insight, particularly in a developing area of medicine where large-scale trials are still emerging.

For clinicians, the value of this resource is practical. It does not attempt to dictate prescribing decisions. Instead, it provides the evidence needed to support them. This includes understanding where CBMPs may be appropriate, where caution is required, and how different patient groups may respond. The launch of the pain evidence base also reflects a broader shift within the sector. As prescribing increases and scrutiny grows, there is a clear need for consistent, evidence-informed approaches. Publications like this play a key role in raising standards, supporting clinicians, and ultimately improving patient care.

Medical cannabis is not a one-size-fits-all treatment. Its place in care needs to be judged case by case, using clear, reliable evidence rather than assumption or anecdote. For clinicians working with complex or treatment-resistant pain, good evidence supports more confident decisions and more consistent care.

Buy the Pain Evidence Base

The Medical Cannabis and Pain Evidence Base is available now for £20, with a discounted rate available for MCCS members.

If you are prescribing, or considering prescribing, this resource provides a structured, clinically relevant review of the evidence to support your decision-making.

➡️ Purchase your copy today

Explore the full Evidence Base Series

This publication forms part of a growing Evidence Base Series, alongside Introduction to Medical Cannabis and Medical Cannabis and Epilepsy, both available to buy now. The next title in the series, Medical Cannabis and Psychiatry, is due to be published soon.

➡️ Explore the full Evidence Base Series

Cannabis-based medicinal products (CBMPs) have been legal to prescribe in the UK since November 2018. Since then, an estimated 95,000 patients have received prescriptions, supported by around 160 prescribers across approximately 40 private clinics. Despite this growth, NHS prescribing remains extremely limited. At the same time, the absence of mandatory training and consistently applied clinical standards has led to variation in practice across the sector.

The Medical Cannabis Clinicians Society (MCCS) has today published an updated version of its Good Practice Guide for Prescribers of CBMPs. This guidance is intended to support clinicians in making safe decisions and strengthen consistent prescribing in a developing area of medicine. It draws on the collective experience of the Society’s multidisciplinary membership, committee and executive, reflecting real-world prescribing across a wide range of clinical settings.

➡️ Download the new Guidance

The Society’s position 

Medical cannabis can be a safe and effective treatment option for selected patients, particularly where conventional therapies have been unsuccessful, when prescribed within a structured clinical framework with appropriate assessment, decision-making and follow-up.

Prescribing must meet the same standards expected of any other unlicensed medicine. Consistent application of these standards is essential to minimise risk for patients and maintain confidence in the sector. This guidance aims to define good practice, based on real-world clinical experience and supported by existing regulatory expectations.

Central to this is clinical responsibility. Prescribing decisions sit with the clinician. They must be justified, based on appropriate assessment, and always remain in the patient’s best interest. This includes independent decision-making and full accountability for documentation, monitoring and outcomes.

This guidance does not replace clinical judgement or existing regulatory frameworks. Medical cannabis remains an individualised treatment, and decisions must be made on a case-by-case basis. The aim is to support safe access to treatment while ensuring prescribing remains clinically appropriate, accountable and evidence informed.

A structured approach within existing regulation

The Good Practice Guide provides a practical framework covering:

These are standard principles of medical practice. The purpose of the guide is to apply them clearly and consistently to cannabis-based medicines. It reflects established principles already recognised by the Society, including careful patient selection, multidisciplinary input where appropriate, and thorough documentation of prescribing decisions.

This guidance sits alongside existing regulatory frameworks. Clinicians must continue to work within the standards set by the General Medical Council, Care Quality Commission, MHRA and NICE. CBMPs remain unlicensed “specials”, and prescribing carries the same responsibilities as any other unlicensed medicine.

The role of the Good Practice Guide is to translate these high-level requirements into practical, day-to-day clinical application, providing clarity on how regulatory expectations apply in the context of medical cannabis.

The Society is committed to working with regulators to support alignment, share clinical expertise and contribute to the development of clear, proportionate and workable oversight as the sector continues to evolve.

Safety in context

Medical cannabis has a favourable safety profile when prescribed appropriately. However, it is not risk-free and requires active clinical oversight. The updated guidance places clear emphasis on risk identification and management. Clinicians are expected to assess, monitor and manage:

Prescribing should follow a cautious, structured approach. This includes starting at low doses, titrating gradually, and maintaining regular follow-up to assess response and tolerability, consistent with established prescribing principles.

What the Good Practice Guide (V4) covers

Raising standards in a developing field

“Prescribing cannabis-based medicinal products requires careful clinical judgment, a strong understanding of the evidence, and a clear grasp of professional responsibilities. This guide provides the structure and support clinicians need to practise safely, lawfully and in the best interests of their patients.”
— Professor Mike Barnes, Chair, Medical Cannabis Clinicians Society

Medical cannabis remains a developing area of medicine. The evidence base continues to evolve, clinical experience is expanding, and expectations around governance are becoming more defined.

The updated guidance provides clinicians with a clear framework for safe, accountable prescribing, and offers reassurance to patients, regulators and the public that medical cannabis is being prescribed within a structured, professionally governed system.

As the sector matures, consistent standards matter. This guidance sets a clear direction for safe, responsible prescribing across the sector.

The MCCS expects this Good Practice Guide to be adopted by prescribers and across clinics, supporting a consistent approach that prioritises patient safety and quality of care. This will help raise standards across clinical practice and the wider sector.

Access the Guide

The Good Practice Guide for Prescribers of CBMPs is available now for all.

If you’re not yet a member, join today to access our growing library of practical tools, prescribing guidance, training, and peer support.

➡️ Download the new Guidance

👉 Find out more and join the Society

Each month, we bring together the key news stories shaping the medical cannabis landscape in the UK and beyond. From policy developments and emerging research to clinical practice, patient experience and sector growth, this update highlights the issues driving debate, influencing care, and affecting access for patients and clinicians alike.

It is designed to keep our members and stakeholders informed, grounded in evidence, and connected to what matters most across this rapidly evolving field.

New medical cannabis campaign launched in memory of Hannah Deacon

Labour MP and long-time medical cannabis advocate, Tonia Antoniazzi, is spearheading a new campaign launched in memory of Hannah Deacon, the mother of Alfie Dingley, who campaigned for the legalisation of medical cannabis in 2018, and went onto co-found the MCCS. Hannah died of cancer last year, aged 45. 

Tonia has called on the government to fund a new observational trial to support children with drug-resistant epilepsy, who are still unable to access medical cannabis on the NHS. The proposed study would run alongside two previously announced NHS-funded randomised controlled trials (RCTs) on medical cannabis and epilepsy, which are being conducted by researchers at UCL. It would allow children who are currently prescribed the treatment privately to continue accessing it at no cost, while real-world data is collected.

🔗 Read more

Patient Protect to support medical cannabis patients facing discrimination

A new UK-wide service supporting medical cannabis patients who face discrimination has launched to fill gaps left by the absence of systematic government support. Patient Protect was founded by patient advocate Alex Fraser and cannabis lawyer Robert Jappie. The service provides guidance, advocacy, and case support for patients encountering issues across policing, employment, housing, and driving-related matters, aiming to collate incidents nationally to build a legal evidence base for systemic reform.

🔗 Read more

Ananda commences NHS-funded endometriosis trial

Ananda Pharma has cleared the final regulatory hurdle needed to begin its ENDOCAN Phase 2 clinical trial, receiving approval from the MHRA and NHS Health Research Authority to commence dosing of its proprietary MRX1 CBD oral solution in women with endometriosis-associated pain.

The milestone marks a significant step forward for a trial that has been in development for several years. The double-blind, placebo-controlled study, led by global endometriosis experts at the University of Edinburgh and funded by the Chief Scientist Office, will include up to 100 women across NHS Lothian and NHS Grampian in Scotland over a 12-week treatment period.

🔗 Read more

Join the Society

If you want to stay informed, supported, and part of the independent clinical voice shaping medical cannabis in the UK, join the Medical Cannabis Clinicians Society.

Membership gives you access to expert guidance, CPD-accredited education, peer support, and regular sector updates like this one. Join the Society to be part of the conversation and help drive better, evidence-based care.

Recent reporting, including in today’s The Times, has raised a number of important questions about medical cannabis prescribing in the UK. These include prescribing volumes, use in psychiatric conditions, product strength, and the death of Oliver Robinson. These are serious issues and require careful, balanced consideration.

The role of the Medical Cannabis Clinicians Society is not to defend or speak for clinics or to promote prescribing. Our role is to support clinicians to practise safely, improve standards, and contribute to the development of a responsible, evidence-informed model of care in a complex and evolving area of medicine.

This article sets out our position.

On the tragic death of Oliver Robinson 

The death of Oliver Robinson was tragic and deeply concerning. Following the publication of the Coroner’s Prevention of Future Deaths Report, we undertook a full review of the findings. This has directly informed a substantial revision of our Good Practice Guidance, due for publication April 2026. The updated guidance strengthens expectations across:

Where standards need to be strengthened, they should be. We would welcome these expectations being adopted more formally within regulatory frameworks to support consistent, high-quality care across the sector.

On psychiatric prescribing and THC content

Prescribing in psychiatric contexts requires particular care.

Treatment is individualised and typically begins with lower-risk approaches, such as CBD-dominant or balanced products, with gradual titration and close monitoring. The aim is to manage symptoms while minimising psychoactive effects and associated risks. 

Higher THC products are not first-line in psychiatric care. Where they are used, this should be based on clear clinical rationale, within a structured specialist framework, and with appropriate oversight. The MCCS Good Practice Guidance advises that prescribing products with THC levels above 25% should involve peer review through a multidisciplinary team.

In some cases, higher THC products may be appropriate. However, presenting their use as routine in mental health care does not reflect standard clinical practice.

On prescribing numbers and growth 

Reporting focused on the number of clinicians responsible for a proportion of prescriptions. It is not appropriate for us too draw conclusions about individual clinicians based on anonymised, aggregate data without clinical context.

Prescribing data reported as “items” does not equate to patient numbers, consultation volume, or complexity of care. For example:

Care in this area is often delivered through structured models, with specialist assessment followed by ongoing prescribing and monitoring, frequently supported by wider clinical teams through shared care. These factors are not captured in headline figures. Aggregate prescribing data alone is not a reliable indicator of care quality or clinical practice.

We recognise the significant growth in prescribing and see this as reflecting sustained patient demand, particularly from people with chronic, treatment-resistant conditions such as pain, anxiety and children with resistant epilepsy who have not found adequate relief from conventional therapies.

This demand sits within a wider system context. Many patients are turning to private care because they are unable to access timely support through the NHS, with long waiting lists, including around 1.7 million people waiting for mental health services, contributing to this shift. Clinicians are responding where standard treatments have not worked, rather than as a first-line approach. 

Clarifying the role of the Society

[*14:21 The Times updated the story to reflect our role accurately]

The Medical Cannabis Clinicians Society has been described as representing private clinics or acting as a trade body. This is not correct.

We are an independent, clinician-led, not-for-profit organisation. We do not represent clinics or commercial providers. Our members are individual healthcare professionals, including consultants, GPs, pharmacists, nurses, and allied health professionals working across a range of settings.

Our role is to support safe, consistent, and evidence-informed prescribing in an area of medicine that has developed without a formal national clinical framework since legalisation in 2018.

This includes:

Clinical responsibility sits with individual prescribers and the organisations in which they work.

Working collaboratively to improve standards

Medical cannabis prescribing in the UK remains a developing area of practice. It requires ongoing scrutiny, transparency, and a willingness to strengthen standards where needed.

We will continue to work with clinicians, regulators, patient groups, and other stakeholders to support the development of clear, consistent, and robust clinical frameworks.

Our focus is unchanged: to support safe, evidence-informed care, and to ensure that patients who may benefit from these treatments can access them within a well-governed clinical system.

Each month, we bring together the key news stories shaping the medical cannabis landscape in the UK and beyond. From policy developments and emerging research to clinical practice, patient experience and sector growth, this update highlights the issues driving debate, influencing care, and affecting access for patients and clinicians alike.

It is designed to keep our members and stakeholders informed, grounded in evidence, and connected to what matters most across this rapidly evolving field.

Medical cannabis patient wins legal fight over wrongful driving conviction

A UK medical cannabis patient has won a Crown Court appeal after being wrongly convicted of driving with THC above the legal limit. At Winchester Crown Court on 10 February 2026, Sal Aziz, a legally prescribed medical cannabis patient, was fully acquitted of the charges after the prosecution failed to prove beyond reasonable doubt that the statutory medical defence did not apply.

While the case does not set a binding precedent, it clarifies the legal position on the use of controlled prescription medication beyond the expiry date. It also highlights the need for clear and consistent guidance on driving when prescribed medical cannabis.

🔗 Read more

Bristol Medical School to offer teaching placement in cannabis-based medicine

Bristol Medical School has formally approved what is believed to be one of the first student-selected medical cannabis teaching placements offered by a UK university. The programme has been developed by Dr David Tang, a Consultant in Emergency Medicine and member of the MCCS Expert Committee. It will introduce students to medical cannabis as a regulated therapeutic intervention within UK clinical practice.

While the study wasn’t designed to evaluate medical cannabis, the thresholds are not intended for use as a THC limit for those being prescribed cannabis, co-author Dr Rachel Lees Thorne said prescribing clinicians will need to “balance the harms and risks of the treatment they provide”.

🔗 Read more

Is ‘reverse spin bias’ an issue in medical cannabis research?

A recent peer-reviewed paper identified a previously unrecognised form of reporting bias that may be skewing how medical cannabis evidence is presented. The paper, published in Research Integrity and Peer Review, introduces the concept of reverse spin bias – a pattern in which authors of systematic reviews “discount, downplay, or dismiss beneficial findings about a treatment despite their own evidence showing statistically significant effects. This phenomenon was observed repeatedly in studies on e-cigarettes for smoking cessation and medical cannabis for pain.

🔗 Read more

France’s medical cannabis reimbursement plans revealed

The French medical cannabis framework is now in the final stage of decision-making before being implemented nationally. The Haute Autorité de Santé (HAS), the body responsible for evaluating medicines and approving them for coverage under France’s public health system, presented a draft for the pricing and reimbursement strategy this month. The proposed model establishes a tiered reimbursement structure tied directly to an assessment of each product’s therapeutic benefit.

🔗 Read more

Join the Society

If you want to stay informed, supported, and part of the independent clinical voice shaping medical cannabis in the UK, join the Medical Cannabis Clinicians Society.

Membership gives you access to expert guidance, CPD-accredited education, peer support, and regular sector updates like this one. Join the Society to be part of the conversation and help drive better, evidence-based care.

Medical schools give students a limited but important amount of protected time to explore subjects outside the core curriculum. Student-selected modules and placements are often the only opportunity students have to step beyond exam-driven learning, follow their curiosity, and engage with areas of medicine that are still evolving.

Legal under prescription in the UK since 2018, medical cannabis is an actively evolving area of practice. While increasingly relevant to everyday clinical practice, it remains poorly covered in undergraduate medical education.

A new student choice placement for 2026

Dr David Tang, Consultant in Emergency Medicine and member of the MCCS Expert Committee, has had his Year 3 MBChB Student Choice placement submission accepted by Bristol Medical School. The placement, Understanding Medical Cannabis: Mechanisms, Indications and Clinical Integration, will be offered to students in 2026.

Dr Tang explains;“As a first-year medical student in 2000, I chose a module on cannabinoid therapeutics as part of my course. Twenty-six years later, medical cannabis is prescribed legally in the UK, patients are asking about it every day, and clinicians are encountering it across multiple specialties. 

But, most medical students still graduate with little understanding of the endocannabinoid system, prescribing frameworks, or how medical cannabis fits into regulated care pathways.

I think that medical graduates should leave university with a basic, evidence-informed understanding of how medical cannabis works, what it may be prescribed for, and where to find reliable guidance. This matters – whether or not they ever go on to prescribe it themselves, because it supports safer clinical conversations, better decision-making, and more informed patient care.”

The placement has been formally approved by Bristol Medical School and will be offered to Year 3 MBChB students as part of their student-selected studies, with allocation due to take place in February 2026.

What the placement will focus on

The placement introduces students to medical cannabis as a regulated therapeutic intervention within UK clinical practice. Structured around three core themes, mechanisms, indications, and clinical integration, the placement will cover:

Teaching will be delivered through seminar-based sessions and facilitated group discussion. Subject to final arrangements, the placement may also include a visit to an EU GMP-licensed medical cannabis cultivation and manufacturing facility, providing insight into how these products are produced to pharmaceutical standards for clinical use.

Part of a wider commitment to students

Dr Tang’s new medical student placement is part of the Medical Cannabis Clinicians Society’s wider commitment to supporting students and early-career clinicians.

Alongside this module, the Society offers:

These initiatives are about giving students access to good information early, space to ask proper questions, and the confidence to engage with an emerging area of medicine thoughtfully and professionally, as it continues to evolve.

Join the Society today.